Warning: The NCBI web site requires JavaScript to function. more...
Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions.
Ligibel JA, Winer EP.
Breast Cancer Res. 2005;7(6):255-7. Epub 2005 Nov 11. Review.
Related citations
Aromatase inhibitors: a new reality for the adjuvant endocrine treatment of early-stage breast cancer in postmenopausal women.
Colozza M, Califano R, Minenza E, Dinh P, Azambuja E.
Mini Rev Med Chem. 2008 Jun;8(6):564-74. Review.
Adjuvant hormonal therapy in early breast cancer.
Kumar S, Leonard RC.
Oncology (Williston Park). 2005 Oct;19(11):1425-8, 1433; discussion 1433-41, 1444-6. Review.
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M.
Clin Ther. 2007 Aug;29(8):1535-47. Review.
Aromatase inhibitors--extending the benefits of adjuvant therapy beyond tamoxifen.
Smith IE.
Breast. 2004 Dec;13 Suppl 1:S3-9. Review.
The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
Rugo HS.
Ann Oncol. 2008 Jan;19(1):16-27. Epub 2007 Aug 9. Review.
Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer.
Sanford M, Plosker GL.
Drugs. 2008;68(9):1319-40. Review.
Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
Wheler J, Johnson M, Seidman A.
Semin Oncol. 2006 Dec;33(6):672-80. Review.
Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Dunn C, Keam SJ.
Pharmacoeconomics. 2006;24(5):495-517. Review.
Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.
Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.
Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
Conte P, Frassoldati A.
Breast J. 2007 Jan-Feb;13(1):28-35. Review.
Advances in adjuvant endocrine therapy for postmenopausal women.
Lin NU, Winer EP.
J Clin Oncol. 2008 Feb 10;26(5):798-805. Review.
Exemestane: a review of its use in postmenopausal women with breast cancer.
Deeks ED, Scott LJ.
Drugs. 2009;69(7):889-918. doi: 10.2165/00003495-200969070-00007. Review.
Update on aromatase inhibitors in breast cancer.
Gould RE, Garcia AA.
Curr Opin Obstet Gynecol. 2006 Feb;18(1):41-6. Review.
Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
Chlebowski RT.
Breast Cancer Res Treat. 2008 Dec;112 Suppl 1:25-34. Epub 2008 Dec 20.
Adjuvant hormonal therapy in peri- and postmenopausal breast cancer.
Ryan PD, Goss PE.
Oncologist. 2006 Jul-Aug;11(7):718-31. Review.
Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Grana G.
J Surg Oncol. 2006 Jun 1;93(7):585-92. Review.
[Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Tuxen MK, Nielsen DL, Lindberg H, Kamby C.
Ugeskr Laeger. 2007 Jan 22;169(4):297-9. Review. Danish.
The aromatase inhibitors as adjuvant therapy for hormone receptor-positive breast cancer.
J Natl Compr Canc Netw. 2003 Apr;1(2):215-21. Review.
The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
Poole R, Paridaens R.
Curr Opin Oncol. 2007 Nov;19(6):564-72. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on